Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Syros Pharmaceuticals, Inc.
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Syros Pharmaceuticals, Inc. since year 2005.
Table 2 shows the detailed insider transactions of Syros Pharmaceuticals, Inc. since 2005.
The reporting company's ticker symbol is SYRS. The reporting company's CIK number is 1556263.
The total value of stock buying since 2005 is $43,537,141.
The total value of stock sales since 2005 is $485,628.
The total value of stock option exercises since 2005 is $240,762.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2018-11-29||Simonian Nancy A (President & CEO)||Option Ex||110,588||2.02||223,940|
|2018-01-31||Akkaraju Srinivas (Director)||Buy||209,424||9.55||1,999,999|
|2017-12-15||Springhorn Jeremy P. (Chief Business Officer)||Buy||15,000||9.08||136,260|
|2017-12-14||Akkaraju Srinivas (Director)||Buy||26,600||8.99||239,134|
|2017-12-13||Akkaraju Srinivas (Director)||Buy||68,400||8.97||613,548|
|2017-12-12||Akkaraju Srinivas (Director)||Buy||14,774||9.40||138,875|
|2017-10-23||Desimone Colleen Elizabeth (Principal Accounting Officer)||Sale||550||16.06||8,833|
|2017-10-23||Desimone Colleen Elizabeth (Principal Accounting Officer)||Option Ex||550||3.04||1,672|
|2017-08-14||Young Richard A (Director)||Sale||3,282||22.00||72,204|
|2017-08-07||Olson Eric R (Chief Scientific Officer)||Sale||2,500||23.59||58,970|
|2017-08-07||Olson Eric R (Chief Scientific Officer)||Option Ex||2,500||1.01||2,525|
|2017-07-25||Olson Eric R (Chief Scientific Officer)||Sale||12,500||21.85||273,125|
|2017-07-25||Olson Eric R (Chief Scientific Officer)||Option Ex||12,500||1.01||12,625|
|2017-07-25||Young Richard A||Sale||3,282||22.09||72,496|
|2016-07-06||Green Jeremy (10% Owner)||Buy||432,746||12.50||5,409,325|
|2016-07-06||Polaris Entrepreneurs' Fund Vii, L.p. (10% Owner)||Buy||400,000||12.50||5,000,000|
|2016-07-06||Deerfield Private Design Fund Iii, L.p.||Buy||400,000||12.50||5,000,000|
|2016-07-06||Nashat Amir (Director)||Buy||400,000||12.50||5,000,000|
|2016-07-06||Purcell Dennis J||Buy||400,000||12.50||5,000,000|
|2016-07-06||Kania Edwin M Jr (10% Owner)||Buy||400,000||12.50||5,000,000|
|2016-07-06||Bybee Clinton (10% Owner)||Buy||400,000||12.50||5,000,000|
|2016-07-06||Nelsen Robert (Director)||Buy||400,000||12.50||5,000,000|
Insider trading activities including stock purchases, stock sales, and option exercises of SYRS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Syros Pharmaceuticals, Inc. (symbol SYRS, CIK number 1556263) see the Securities and Exchange Commission (SEC) website.